Autoamplification of NFATc1 expression determines its essential role in bone homeostasis by Asagiri, Masataka et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 202, No. 9, November 7, 2005 1261–1269 www.jem.org/cgi/doi/10.1084/jem.20051150
 
ARTICLE
 
1261
 
Autoampliﬁcation of NFATc1 expression 
determines its essential role 
in bone homeostasis
 
Masataka Asagiri,
 
1,4,5
 
 Kojiro Sato,
 
1,4,5
 
 Takako Usami,
 
7
 
 Sae Ochi,
 
1,2,4
 
 
Hiroshi Nishina,
 
8
 
 Hiroki Yoshida,
 
6,9
 
 Ikuo Morita,
 
3,4
 
 Erwin F. Wagner,
 
10
 
 
 
Tak W. Mak,
 
11,12
 
 Edgar Serﬂing,
 
13
 
 and Hiroshi Takayanagi
 
1,4,5
 
1
 
Department of Cell Signaling 
 
2
 
Department of Medicine and Rheumatology, 
 
3
 
Department of Cellular Physiological Chemistry, 
Graduate School, and 
 
4
 
Center of Excellence Program for Frontier Research on Molecular Destruction and Reconstruction 
of Tooth and Bone, Tokyo Medical and Dental University, Tokyo 113-8549, Japan
 
5
 
Solution Oriented Research for Science and Technology and 
 
6
 
Precursory Research for Embryonic Science and Technology, 
Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012, Japan
 
7
 
Laboratory of Recombinant Animals and 
 
8
 
Department of Developmental and Regenerative Biology, Medical Research Institute, 
Tokyo Medical and Dental University, Tokyo 101-0062, Japan
 
9
 
Department of Biomolecular Sciences, Faculty of Medicine, Saga University, Saga City, Saga 849-8501, Japan
 
10
 
Research Institute of Molecular Pathology, A-1030 Vienna, Austria
 
11
 
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Ontario M5G 2M9, Canada
 
12
 
Department of Medical Biophysics, Advanced Medical Discovery Institute, University of Toronto, Toronto, Ontario M5G 2C1, Canada
 
13
 
Department of Molecular Pathology, Institute of Pathology, University of Wüerzburg, D-97080 Wüerzburg, Germany
 
NFATc1 and NFATc2 are functionally redundant in the immune system, but it was suggested 
that NFATc1 is required exclusively for differentiation of osteoclasts in the skeletal system. 
Here we provide genetic evidence that 
 
NFATc1
 
 is essential for osteoclast differentiation in 
vivo by adoptive transfer of 
 
NFATc1
 
   
 
 hematopoietic stem cells to osteoclast-deficient 
 
Fos
 
   
 
 
mice, and by 
 
Fos
 
   
 
 blastocyst complementation, thus avoiding the embryonic lethality of 
 
NFATc1
 
   
 
 mice. However, in vitro osteoclastogenesis in 
 
NFATc1
 
-deficient cells was rescued 
by ectopic expression of NFATc2. The discrepancy between the in vivo essential role of 
 
NFATc1
 
 
and the in vitro effect of NFATc2 was attributed to selective autoregulation of the 
 
NFATc1
 
 
gene by NFAT through its promoter region. This suggested that an epigenetic mechanism 
contributes to the essential function of 
 
NFATc1
 
 in cell lineage commitment. Thus, this study 
establishes that 
 
NFATc1
 
 represents a potential therapeutic target for bone disease and reveals 
a mechanism that underlies the essential role of 
 
NFATc1
 
 in bone homeostasis.
 
The mechanism underlying irreversible cell fate
determination is critical for an understanding
of biologic systems in vertebrates, where the
NFAT family of transcription factors plays
important roles (1, 2). Mice deficient in individ-
ual  NFAT proteins exhibit a relatively mild
phenotype in immune cells or neurons (1, 2),
which suggests that the different family members
play redundant roles in these systems (1–3).
Homeostasis of the skeletal system depends on a
balance between bone-forming osteoblasts and
bone-resorbing osteoclasts (4). The critical role
of 
 
NFATc1
 
 in the skeletal system was suggested
by selective and strong induction of 
 
NFATc1
 
 in
bone marrow monocyte/macrophage precursor
cells (BMMs) that were stimulated with a key
cytokine for osteoclastogenesis, receptor activator
of NF-
 
 
 
B ligand (RANKL) (5, 6). Although
our previous in vitro analyses indicated that
NFATc1 is the essential transcription factor for
osteoclast differentiation (5), little is known
about its in vivo function in osteoclastogenesis
because targeted disruption of the 
 
NFATc1
 
gene in mice results in embryonic lethality.
Furthermore, there is a contrasting report that
NFATc2 also activates this process and may
have a redundant role (7). Considering the close
functional similarity of NFATc1 and NFATc2
(3, 7), it is important to determine whether
 
NFATc1
 
 is essential for osteoclast differentiation
in vivo, and, if so, how it exerts an indispensable
function in this cell type.
In this report, we provide in vivo genetic
evidence for the essential role of 
 
NFATc1
 
 by
two novel techniques: adoptive transfer of
hematopoietic stem cells to osteoclast-deficient
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Fos
 
 
 
/
 
 
 
 mice and 
 
Fos
 
-deficient blastocyst complementa-
tion. 
 
NFATc1
 
-deficient osteoclast precursor cells cannot dif-
ferentiate into osteoclasts. Conversely, osteoclastogenesis
of 
 
NFATc1
 
-deficient cells is rescued by forced expression of
NFATc2. The discrepancy between the essential role of
 
NFATc1
 
 and the in vitro effect of NFATc2 is attributed to
selective autoregulation of the 
 
NFATc1
 
 gene by NFAT
through its promoter region. Our analysis indicates that the
essential role of NFATc1 in bone homeostasis is not deter-
mined by its distinct biochemical properties, but is deter-
mined by its unique spatiotemporal activation mechanism
during osteoclastogenesis.
 
RESULTS
In vivo evidence for the essential role of 
 
NFATc1
 
 in osteoclast 
differentiation shown by the fetal liver cell (FLC) transfer
 
Because in vivo analysis of the role of 
 
NFATc1
 
 has been ham-
pered by embryonic lethality (8, 9), one may postulate that a
conditional gene targeting strategy should be appropriate to
avoid the difficulty. However, there is no desirable promoter to
drive 
 
cre
 
 (encoding Cre recombinase) in the very early stage of
osteoclast development. Adoptive transfer of hematopoietic
stem cells to irradiated lymphocyte-deficient mice (10, 11) is
used as an established method to analyze the function of such a
gene in the study of lymphocytes (3). Here we applied this
method to the skeletal system using mice lacking 
 
c-Fos
 
 (
 
Fos
 
 
 
/
 
 
 
mice) (12, 13) as osteoclast-deficient recipients. Hematopoietic
stem cells that were derived from 
 
NFATc1
 
 
 
/
 
 
 
 and 
 
NFATc1
 
 
 
/
 
 
 
FLCs were injected into the liver of busulfan-treated newborn
mice of 
 
Fos
 
 
 
/
 
 
 
 background, in which no osteoclasts form be-
cause of a cell autonomous defect (13). Osteopetrosis is amelio-
 
Figure 1. In vivo evidence for the essential role of 
 
NFATc1
 
 
 
in 
osteoclast differentiation.
 
 (A) Radiographic analysis of 
 
Fos
 
 
 
/
 
 
 
 mice 
transferred with 
 
NFATc1
 
 
 
/
 
 
 
 or 
 
NFATc1
 
 
 
/
 
 
 
 FLCs. Severe osteopetrosis persists 
after 
 
NFATc1
 
 
 
/
 
 
 
 FLC transfer. (B) Microradiographic analysis of femur 
(left: microcomputed tomography; right: microradiograph). Bone marrow 
cavity is filled with unresorbed bone in 
 
NFATc1
 
 
 
/
 
 
 
 FLC chimera. (C) Histologic 
examination of tibia (top: toluidine blue staining; middle: tartrate-resistant 
acid phosphatase [TRAP] staining for detection of osteoclasts and lumbar 
vertebra; bottom: toluidine blue staining). No osteoclasts are observed in 
 
NFATc1
 
 
 
/
 
 
 
 FLC chimera. (D) Histomorphometric evaluation of osteoclasts 
in 
 
NFATc1
 
 
 
/
 
 
 
 and 
 
NFATc1
 
 
 
/
 
 
 
 FLC chimera. (E) Reconstitution of the he-
matopoietic system of chimeric mice by the donor cells. PCR primers specific 
for joint region between the 
 
NFATc1
 
 locus and the neomycin-resistant 
gene (
 
NFATc1 neo
 
) and for wild-type (WT) 
 
NFATc1
 
 gene
 
 
 
are used. The similar 
chimeric ratios were confirmed by quantitative PCR. (F) Complete blockade 
of in vitro osteoclastogenesis in osteoclast precursor cells from 
 
NFATc1
 
 
 
/
 
 
 
 
FLC chimera. Splenocyte-derived osteoclast precursor cells were cultured 
in RANKL (50 ng ml
 
 
 
1
 
) and M-CSF (10 ng ml
 
 
 
1
 
). We counted multinucleated 
(
 
 
 
3 nuclei) cells (MNCs) positive for TRAP staining. (G) Radiographic 
analysis of neonates generated by 
 
Fos
 
 
 
/
 
 
 
 blastocyst complementation. 
Note the difference in radio-opacity at the femur (arrowheads). Right pan-
els show the magnified view of the femur of neonates and tooth eruption of 
6-wk-old mice. All of the 
 
Fos
 
 
 
/
 
 
 
/
 
NFATc1
 
 
 
/
 
 
 
 chimeric mice exhibited 
osteopetrosis, but osteoclastogenesis is restored in 
 
Fos
 
 
 
/
 
 
 
/NFATc1
 
 
 
/
 
 
 
 
chimeric mice when ES cells are transmitted to the hematopoietic system 
of recipient mice. **P 
 
 
 
 0.001 versus control. 
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rated and bone marrow cavities are observed when 
 
NFATc1
 
 
 
/
 
 
 
FLCs are transferred to 
 
Fos
 
 
 
/
 
 
 
 mice (Fig. 1, A and B). Tooth
eruption, which is not seen in 
 
Fos
 
 
 
/
 
 
 
 mice (13), is observed in
these mice (unpublished data). In contrast, when 
 
NFATc1
 
 
 
/
 
 
 
FLCs are transferred to 
 
Fos
 
 
 
/
 
 
 
 mice, they exhibit severe osteo-
petrosis and bone marrow cavities remain occupied with unre-
sorbed bone (Fig. 1, A and B). Histologic analyses show that
osteoclast number and parameters of bone resorption are nor-
malized only when 
 
NFATc1
 
 
 
/
 
 
 
 cells are transferred (Fig. 1, C
and D). Repopulation of hematopoietic cells was confirmed by
PCR in splenic lymphocytes and monocyte/macrophage pre-
cursor cells (Fig. 1 E). Consistently, osteoclast precursor cells
that were derived from the 
 
NFATc1
 
 
 
/
 
 
 
 FLC chimera could
not generate osteoclasts in culture (Fig. 1 F). These results indi-
cate that 
 
NFATc1
 
 is indispensable for osteoclast formation in
vivo, and that FLC transfer to osteoclast-deficient mice is a
beneficial tool for in vivo analysis of the osteoclast lineage.
Fos    blastocyst complementation
Rag-2–deficient blastocyst complementation is an alternative
method for analyzing the lymphocyte-specific functions of
gene, loss of which results in embryonic lethality (14). To
provide additional genetic evidence for the essential role of
NFATc1 in osteoclastogenesis, we applied this method to an
analysis of the osteoclast lineage using Fos /  blastocysts (re-
ferred to as Fos-deficient blastocyst complementation). We
analyzed chimeric neonates that were generated by injection
of wild-type or NFATc1 /  embryonic stem (ES) cells into
Fos /  blastocysts. The chimeric mice that result from injec-
tion of normal ES cells into Fos /  blastocysts (Fos / /
NFATc1 /  chimera) should develop mature osteoclasts,
which are derived from the injected ES cells. In fact, all of the
chimeric mice recovered from osteopetrosis, and tooth erup-
tion was observed when the injected ES cells were transmitted
into the hematopoietic lineage (Fig. 1 G). In contrast, chi-
meric mice that result from injection of NFATc1 /  ES cells
into Fos /  blastocysts (Fos / /NFATc1 /  chimera) remain
severely osteopetrotic, and have a defect in tooth eruption that
is due to a lack of osteoclasts (Fig. 1 G and not depicted).
Taken together with the results of FLC transfer, these obser-
vations provide clear evidence that NFATc1 is essential for
osteoclast differentiation in vivo.
NFATc2 is dispensable for osteoclastogenesis in vivo 
and in vitro
NFATc2 is another NFAT protein that is expressed at a low
level in osteoclast precursor cells (5, 7). In addition to the simi-
larity of the DNA binding (Rel homology) domain, the ge-
nomic view of the NFATc1 and NFATc2 loci suggest that
NFATc2 is the evolutionally closest relative of NFATc1
among the NFAT proteins (1, 2, 15, 16) (Fig. 2 A). In addi-
Figure 2. In vitro compensation of NFATc1 deficiency by forced 
expression of NFATc2. (A) Phylogenetic tree analysis for the DNA 
binding (Rel homology) region of NFAT family proteins (top). A wide-
range genomic view of NFATc1 and NFATc2 genes suggests that these 
genes were generated by chromosomal gene duplication (bottom). 
(B) Loss-of-function analyses of NFATc2 in osteoclast differentiation. 
Microradiographic analysis of femur derived from NFATc2 /  mice at 
5 wk of age (see Fig. 1 B). (C) Histologic examination of tibia from NFATc2 /  
mice (left: toluidine blue staining; right: tartrate-resistant acid phosphatase 
staining [TRAP]). (D) Recovery of osteoclastogenesis in NFATc1 /  FLCs by 
retrovirus-mediated expression of NFATc1 or NFATc2. Forced expression 
of NFATc2 as well as that of NFATc1 induces formation of osteoclasts 
with pit-forming activity on dentin slices (RANKL, 50 ng ml 1). Infection 
efficiency was monitored by GFP, which is expressed bicistronically. 
**P   0.001 versus mock.EPIGENETIC REGULATION OF NFAT IN OSTEOCLASTS | Asagiri et al. 1264
tion, overexpression of NFATc2 facilitates the differentia-
tion of osteoclasts (7) (Fig. S1, available at http://www.
jem.org/cgi/content/full/jem.20051150/DC1). These results
prompted us to investigate osteoclast differentiation in NFATc2-
deficient (NFATc2 / ) mice (17). Although NFATc2 is in-
volved in the regulation of chondrocytes at advanced age, bone
development of NFATc2 /  mice has never been well defined
(18). Skeletal development occurs normally, and we observed
no increase in bone mass in NFATc2 /  mice as shown in Fig.
2 B [see also reference 19]. We found no abnormality in the
number of osteoclasts, or in the parameters of osteoclastic bone
resorption (Fig. 2 C and Fig. S2, available at http://www.jem.
org/cgi/content/full/jem.20051150/DC1) in NFATc2 / 
mice. Consistently, NFATc2 /  BMMs that are stimulated by
RANKL normally differentiate into osteoclasts with bone-
resorbing activity (Fig. S3, available at http://www.jem.org/
cgi/content/full/jem.20051150/DC1 and not depicted). In
addition, RANKL induction of NFATc1 in NFATc2 /  cells
is comparable to that in NFATc2 /  cells (Fig. S3). Thus,
NFATc2 is dispensable for RANKL-induced NFATc1 expres-
sion and osteoclastogenesis. 
Osteoclast differentiation of NFATc1-deficient cells 
is rescued by forced expression of NFATc2
Because NFATc1 and NFATc2 have a similar ability to acti-
vate gene expression in T cells (1–3), it has been unexpected
that NFATc1 plays a nonredundant role in the skeletal system.
NFATc1 /  cells differentiate into osteoclasts with bone-
Figure 3. Autoamplification of NFATc1 during osteoclastogenesis. 
(A) GeneChip analysis of mRNA expression of NFATc1 and NFATc2 in 
RANKL-stimulated BMMs. Strong induction of NFATc1 by RANKL is inhibited 
by FK506 (2.5  g ml 1), which inhibits NFAT activity. NFATc2 expression 
is constitutive and is not affected by FK506. (B) Semiquantitative RT-PCR 
analysis of the mRNA of NFATc1 isoforms in BMMs. NFATc1/A is induced 
 10-fold by RANKL. (C) Immunoblot analysis of NFATc1 isoforms during 
RANKL-induced osteoclastogenesis in BMMs. A Daudi lymphoma cell line 
is shown as a positive control for all three isoforms (A, B, and C) of 
NFATc1 (22). (D) A schematic illustration of putative transcription factor 
binding sites in the 5  flanking region of the NFATc1 (20) and NFATc2 
genes. Binding sites in the 5  flanking region of the NFATc2 gene were 
determined by the TRANSFAC retrieval program. Arrows indicate primers 
for ChIP experiments. (E) ChIP assay of NFATc1 and NFATc2 promoters in 
RANKL-stimulated BMMs. (F) Luciferase assay of NFATc1 and NFATc2 
promoters in HEK293T cells.JEM VOL. 202, November 7, 2005 1265
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resorbing activity when they are stimulated by RANKL in the
presence of M-CSF, whereas NFATc1 /  cells are unable to
generate osteoclasts (Fig. 2 D), despite normal development
into the monocyte/macrophage lineage (Fig. S4, available at
http://www.jem.org/cgi/content/full/jem.20051150/DC1).
To investigate the function of NFATc1 and NFATc2 further,
we ectopically expressed NFATc1 and NFATc2 under the
control of the LTR promoter using retrovirus-mediated gene
transfer (20) in NFATc1 /  osteoclast precursor cells. As ex-
pected, the formation of bone-resorbing osteoclasts was res-
cued by retroviral expression of NFATc1. Surprisingly, osteo-
clast formation recovered, albeit at a reduced efficiency, as the
result of forced expression of NFATc2. This demonstrated that
forced expression of NFATc2 compensates for the loss of the
NFATc1 gene (Fig. 2 D).
Selective autoamplification of NFATc1 
during osteoclastogenesis
How can we reconcile the in vivo essential role of NFATc1 in
osteoclastogenesis with the observation that NFATc1 deficiency
is compensated for by forced expression of NFATc2? Whereas
NFATc2 is expressed constitutively in BMMs at a low level,
mRNA of NFATc1 is induced selectively and potently by
RANKL (5) (Fig. 3 A). The induction of NFATc1, but not
NFATc2, is down-regulated by the calcineurin inhibitor,
FK506, which suppresses the activity of NFAT (Fig. 3 A). This
suggests that NFATc1 is autoregulated selectively by NFAT
when BMMs are stimulated with RANKL, and that the result-
ing expression pattern may explain the specificity of NFATc1.
Although NFATc1 also is autoregulated in T cells (20, 21), the
expression pattern during osteoclastogenesis (autoamplification)
is characterized by a monotone increase and magnitude of am-
plification. Three isoforms (A, B, and C) of NFATc1 are well
documented in T cells (20, 22), but it remains to be clarified
which isoform is involved in osteoclastogenesis. Using specific
PCR primers, we found that mRNA expression of the shortest
isoform, NFATc1/A, is induced selectively in RANKL-stimu-
lated BMMs (Fig. 3 B); immunoblot analysis yielded consistent
results (Fig. 3 C). Therefore, we investigated the regulatory
mechanism of the P1 promoter of the NFATc1 gene, which
regulates NFATc1/A induction (20), in comparison with the
NFATc2 promoter. To determine the transcriptional start site of
mouse NFATc2 gene, a 5  rapid amplification of cDNA ends
experiment was performed. The putative transcription factor
binding sites in the 5  flanking region of the NFATc1 and
NFATc2 gene are shown in Fig. 3 D. Unexpectedly, these re-
sults suggest that not only the NFATc1 promoter but also the
NFATc2 promoter contain multiple NFAT binding sites.
Recruitment of NFATc1 and other transcription factors 
to the NFAT promoters
Chromatin immunoprecipitation (ChIP) analysis shows that
NFATc2 is recruited to the NFATc1 promoter at the earliest
phase of osteoclast differentiation (Fig. 3 E). 24 h after
RANKL stimulation, NFATc1 mainly occupies the promoter
instead of NFATc2, and c-Fos is concomitantly recruited to
the promoter (Fig. 3 E); this is consistent with the strong in-
duction of NFATc1 at this time point. This occupancy persists
during terminal differentiation of osteoclasts, and indicates that
autoamplification of NFATc1 occurs during this process and
that c-Fos may contribute to it. This is congruent with the
critical role of c-Fos in RANKL-mediated induction of
NFATc1, which was reported previously (5, 23). NF- B is
activated rapidly by RANKL (24), and a recent study suggests
that NF- B activity is important for RANKL-mediated in-
duction of NFATc1 at the early phase of osteoclastogenesis
(25). Consistent with this, NF- B components p50 and p65
are recruited to the NFATc1 promoter 1 h after RANKL
stimulation. However, this recruitment is not observed after
24 h (Fig. 3 E), which suggests that NF- B is important
for the initial induction of NFATc1 in cooperation with
NFATc2. Although NFATc2 is detected on the NFATc1
promoter without RANKL stimulation, NFATc1 is not in-
duced under this condition, which suggests that additional
stimulation, such as NF- B activation, is important for the ef-
ficient triggering of this promoter. This is consistent with the
observation in the luciferase assay that the NFATc1 promoter
is not activated fully by NFATc2 alone, but is activated mark-
edly by the coexpression of NFATc2 and NF- B (Fig. 3 F).
The basal calcineurin activity in osteoclast precursor cells may
contribute to the nuclear localization of NFATc2 without
RANKL addition (Fig. S5, available at http://www.jem.org/
cgi/content/full/jem.20051150/DC1). Because osteoclast dif-
ferentiation was not affected in NFATc2 /  mice, the func-
tion of NFATc2 evidently can be compensated by other fac-
tors, although it may contribute to physiologic regulation of
the initial induction of NFATc1. A reporter plasmid that is
driven by the NFATc1-P1 promoter, but not by the NFATc2
promoter, is activated markedly by NFAT in cooperation
with NF- B (Fig. 3 F). These results indicate that the
NFATc1 promoter is distinct from the NFATc2 promoter in
that the former is exclusively under autoregulation by NFAT;
this further suggests that an autoregulatory mechanism con-
tributes to the essential role of NFATc1.
Epigenetic regulation of NFATc1 gene determines its unique 
spatiotemporal induction pattern during osteoclastogenesis
To gain insight into the selective recruitment of NFATc1
to the NFATc1 promoter, we examined the association of
transcriptional cofactors with these promoters. NFATc1
promoter is associated increasingly with transcriptional co-
activators with histone acetylase activity, such as CREB-
binding protein (CBP) and p300/CBP-associated factor
(PCAF), but is dissociated with histone deacetylase 1
(HDAC1; Fig. 4 A). It is notable that histone acetylation in
the NFATc1 promoter increased gradually after RANKL
stimulation and that the high acetylation status was sus-
tained, but this was not observed in the NFATc2 promoter
(Fig. 4 B). Methylation of histone H3 lysine 4, which is
characteristic of the transcriptionally active locus, is up-
regulated exclusively in the NFATc1 promoter (Fig. 4
B). Conversely, the NFATc2 promoter is associated con-EPIGENETIC REGULATION OF NFAT IN OSTEOCLASTS | Asagiri et al. 1266
stantly with methylated DNA-binding proteins, such as the
methyl-CpG binding protein 2 (MeCP2) (Fig. 4 C), which
suggests that the NFATc2 promoter specifically is silenced
during osteoclast differentiation. Consistent with this no-
tion, we detected high levels of methylated histone H3
lysine 9 only in the NFATc2 promoter (Fig. 4 C). These
results suggest that epigenetic regulation underlies the spe-
cific autoamplification of NFATc1.
DISCUSSION
Our results illustrate that the essential importance of a gene is
not only attributable to the specific biochemical function of
the coded protein, but also is determined epigenetically by
the distinct regulatory mechanism of gene expression. The
role of GATA-1 and GATA-3 in erythropoiesis and Th2 cell
differentiation are examples in which the essential impor-
tance of one member of a group of structurally related pro-
Figure 4. Epigenetic regulation of NFATc1 promoter underlies the 
selective autoamplification of NFATc1. (A) Analysis of chromatin mod-
ification–related factors in NFATc1 and NFATc2 promoters by ChIP in RANKL-
stimulated BMMs during osteoclastogenesis. (B) ChIP assay for acetylated 
histone and methylated histone H3 lysine 4. (C) ChIP assay for MeCP2 and 
methylated histone H3 lysine 9. (D) A schematic diagram of three stages of 
osteoclast differentiation that are governed by NFATc1. (i) NFATc2 is recruited 
to the NFATc1 promoter at the very early phase, but this is not enough to 
activate the NFATc1 promoter. The binding of RANKL to receptor activator of 
NF- B (RANK) results in the recruitment of TNF receptor–associated factor 
(TRAF) 6, and leads to the activation of downstream molecules, such as NF- B 
(25, 34). Cooperation of NFATc2 and NF- B activates the initial induction of 
NFATc1, but because NFATc2-deficient mice have no obvious defect in 
osteoclast differentiation, unknown factor(s) (shown as X) may compensate 
for the loss of NFATc2 in these mice. (ii) RANKL–RANK interaction cooperates 
with immunoreceptors to activate the calcium signals (28), which stimulate 
the NFATc1 activation by way of calcineurin (5). NFATc1 bind to its own 
promoter, which leads to the robust induction of NFATc1; AP-1 (containing 
c-Fos) is critical for this autoamplification. Selective recruitment of NFATc1 
to the promoter of NFATc1, but not NFATc2, is explained in part, by epigenetic 
regulation. (iii) Several osteoclast-specific genes, such as cathepsin K, TRAP, 
and calcitonin receptor, are activated by a transcriptional complex that con-
tains NFATc1 and other cooperators, such as AP-1, PU.1, and microphthalmia-
associated transcription factor (MITF).JEM VOL. 202, November 7, 2005 1267
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teins of interchangeable function is based on an autoreg-
ulatory mechanism (26, 27). These studies suggest that
autoregulation of transcription factors is one of the critical
mechanisms for cell fate determination (2). In a future study,
generation of mice with an NFATc2 knock-in into the
NFATc1 locus will be an intriguing strategy to provide the
conclusive in vivo evidence.
As depicted in Fig. 4 D, in the differentiation of osteo-
clasts, preexisting NFATc2 cooperates with other RANKL-
stimulated transcription factors, such as NF- B, to activate
the initial induction of NFATc1, followed by an autoampli-
fication phase of NFATc1. It was reported that the activator
protein (AP)–1 component, c-Fos, is critical for RANKL-
mediated induction of NFATc1 (5, 23). Consistent with
this, c-Fos is recruited selectively to the NFATc1 promoter
at the autoamplification phase (Fig. 3 E). The composite
NFAT/AP-1 site is observed exclusively in the NFATc1
promoter (Fig. 3 D) (20). This lends further support to the
notion that the cooperation of NFAT and AP-1 is respon-
sible for the specific activation of the NFATc1 promoter
and its autoamplification.
Calcium signal-mediated activation of NFATc1 also trig-
gers the autoamplification loop of NFATc1 and ensures a sus-
tained NFATc1-dependent transcriptional program (5, 28) in
which osteoclast-specific genes are activated by a transcrip-
tional complex that involves NFATc1, AP-1, and other coop-
erators (5, 29). Accumulating evidence indicates that NFATc1
regulates many osteoclast-specific genes, such as cathepsin K
(29), TRAP (5, 30), calcitonin receptor (5, 30), and osteoclast-asso-
ciated receptor (30), in cooperation with other transcription fac-
tors (e.g., PU.1 and microphthalmia-associated transcription
factor), although the components of the transcriptional com-
plex are not always the same (30) (Fig. 4 D, iii). A distinct pat-
tern of calcium oscillation, which efficiently keeps NFATc1
transcriptionally active in the nucleus (31), may explain the
specific spaciotemporal expression of NFATc1 in the osteo-
clast lineage (5), in contrast to T cells. FK506 inhibited osteo-
clast formation, even when it was added at the late phase of
osteoclastogenesis (48–72 h after RANKL stimulation, un-
published data); this suggests that calcium signaling is also critical
for the autoamplification of NFATc1.
Successful application of FLC transfer and blastocyst com-
plementation, first established in the immune system, pro-
vided genetic evidence that NFATc1 is essential for osteoclast
differentiation and maintenance of the skeletal system. Mod-
ulation of the NFATc1 autoamplification pathway has
promise as a strategy for suppressing the excessive osteoclast
formation that is characteristic of a variety of bone diseases.
MATERIALS AND METHODS
Mice and analysis of bone phenotype. Generation of Fos /  and
NFATc1 /  mice has been described previously (8, 13). NFATc2 mice (17)
were provided by L.H. Glimcher (Harvard Medical School, Boston, MA). His-
tologic, histomorphometric, and microradiographic examinations were per-
formed using essentially the same methods as described (32). Statistical analysis
was performed using Student’s t test. All mice were kept in a specific pathogen-
free environment, and all animal experiments were performed with the ap-
proval of the institutional committee of Tokyo Medical and Dental University.
In vitro osteoclastogenesis and retroviral gene transfer. Bone mar-
row cells or FLCs were cultured in  -MEM (GIBCO BRL) containing 10%
FBS (Sigma-Aldrich) and 10 ng ml 1 M-CSF (R&D Systems). After 2 d, ad-
herent cells were used as osteoclast precursor cells. In osteopetrotic mice, os-
teoclast precursor cells were obtained similarly from splenocytes. We de-
scribed the method of RANKL-induced in vitro osteoclastogenesis, retroviral
gene transfer, characterization of osteoclasts, and immunostaining (5, 24, 32).
All data are expressed as mean   SEM (n   6). Retroviral vectors, pEGZ-
NFATc1/A (NFATc1 virus) and pEGZ-NFATc2 (NFATc2 virus), were de-
scribed previously (20), and infection efficiencies of both retrovirus vectors
into osteoclast precursor cells were  40%, as described previously (24).
Fetal liver cell transfer. NFATc1 /  and NFATc1 /  embryos were
obtained by crossing NFATc1 /  parental mice. Total liver cells (107 cells)
from embryonic day (E) 13.5 embryos were injected into the liver of re-
cipient Fos /  newborn (2 d) mice, which were analyzed at 6 wk of age.
The recipient mice were treated with busulfan (Sigma-Aldrich) in utero
by i.p. administration to pregnant mice (12.5 mg kg 1) twice at 17.5 and
18.5 d postcoitum.
Fos    blastocyst complementation. Establishment of NFATc1 /  ES
cell lines has been described (33). NFATc1 /  ES cells or wild-type ES cells
(E14K) were injected into E3.5 Fos /  blastocysts that were obtained by
fertilizing Fos /  gametes from Fos /  paternal and maternal mice using
in vitro fertilization technique. Resultant blastocysts were transferred to
pseudopregnant foster mothers to generate chimeric mice.
RT-PCR and GeneChip analysis. RNA extraction, semiquantitative
RT-PCR, and GeneChip analysis were performed as described previously (5,
32). The following PCR primers were used to detect NFAT isoforms.
NFATc1/A: 5 -GGTAACTCTGTCTTTCTAACCTTAAGCTC-3  (sense)
and 5 -GTGATGACCCCAGCATGCACCAGTCACAG-3  (antisense);
NFATc1/B: 5 -CCCATCCGCCAGGCTACAGCCGCAGTAA-3  (sense)
and 5 -TTCGGTAAGTTGGGATTTCTGAGTGGTACC-3  (antisense);
NFATc1/C: 5 -CCCATCCGCCAGGCTACAGCCGCAGTAA-3  (sense)
and 5 -TGAGTGGTACCAGATGTGGGTCCAGTTTAT-3  (antisense).
Chromatin immunoprecipitation. ChIP was performed with the ChIP
Assay Kit (Upstate Biotechnology) according to the manufacturer’s instruc-
tions, using antibodies against NFATc1, NFATc2, p300/CBP-associated
factor, histone deacetylase 1, p50, CBP, MeCP2 (Santa Cruz Biotechnol-
ogy, Inc.), p65, acetylated histone, mono/di/trimethyl-histone H3 lysine 4,
dimethyl-histone H3 lysine 9 (Upstate Biotechnology), c-Fos (Calbio-
chem), and normal IgG (Santa Cruz Biotechnology, Inc.). The purified
DNA was analyzed by PCR using primers that detect sequences containing
the  NFATc1-P1 promoter: 5 -CCGGGACGCCCATGCAATCTGT-
TAGTAATT-3  (sense) and 5 -GCGGGTGCCCTGAGAAAGC-
TACTCTCCCTT-3  (antisense) and the NFATc2 promoter: 5 -TTAT-
CAGGGAGCACTGCCCATCTCCGCTTT-3  (sense) and 5 -
CGGTCTGGCCTGAGCGACAGGCCCAGACAA-3  (antisense).
Luciferase reporter gene assay. The reporter plasmid pNFATc1P1-0.8
kb-luc (pNFATc1-pr-luc) was described previously (20). pNFATc2-0.8
kb-luc (pNFATc2-pr-luc) was constructed by inserting a 0.8-kb NheI–Xho
fragment of the mouse NFATc2 promoter into the same sites of the pGL3
basic promoter vector (Promega). The mouse NFATc2 promoter region
was amplified by PCR using following primers: 5 -GCTAGCTGTTTTG-
GTGACTGTTATCATGCTGGG-3  (sense) and 5 -CTCGAGCTTC-
CTGCTCAAGGCACCTGTTGCAG-3  (antisense). Transfection into
HEK293T cells and measurement of luciferase activity were performed as
described (5) using the Dual-luciferase reporter assay system (Promega).EPIGENETIC REGULATION OF NFAT IN OSTEOCLASTS | Asagiri et al. 1268
Online supplemental material. Fig. S1 shows the gain-of-function
analyses of NFATc1 and NFATc2 in osteoclasts. Fig. S2 shows the histo-
morphometric evaluation of osteoclasts in NFATc2 /  mice. Fig. S3 shows
the normal osteoclast differentiation and expression of NFATc1 in
NFATc2 /  monocyte/macrophage precursor cells that were stimulated
with RANKL/M-CSF. Fig. S4 shows the development into the monocyte/
macrophage lineage from NFATc1 /  FLCs. Fig. S5 shows the effect of
FK506 on the recruitment of NFATc2 to the NFATc1 promoter without
RANKL stimulation. Also, details of the methods for phylogenetic tree
analysis and 5  rapid amplification of cDNA ends analysis are available. On-
line supplemental material is available at http://www.jem.org/cgi/content/
full/jem.20051150/DC1.
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